Systemic IgG Versus Mucosal IgA

Jonas Salk's Killed Poliovirus, the Cutter Disaster, and Albert Sabin's Live Attenuated Strains

Throughout the first half of the twentieth century, poliomyelitis presented an epidemiological paradox: improved urban sanitation and clean water supplies increased the incidence of childhood paralysis. Poliovirus is a non-enveloped positive-sense RNA enterovirus transmitted via the fecal-oral route. When infants in unsanitary conditions ingested the virus during the first months of life while protected by maternal antibodies, they experienced silent enteric infections that conferred lifelong immunity. In sanitized cities, children escaped infant exposure and encountered the virus later with zero circulating antibodies. In roughly 99 percent of infections, poliovirus replication remains confined to the oropharynx and the Peyer's patches of the ileum. In 0.5 to 1 percent of cases, persistent viremia breaches the blood-brain barrier and invades the anterior horn motor neurons of the spinal cord or the brainstem bulbar nuclei, causing irreversible flaccid paralysis.

Two mid-century discoveries made a vaccine possible. Between 1948 and 1951, Isabel Morgan at Johns Hopkins and the National Foundation for Infantile Paralysis typing committee established that all clinical isolates belonged to three immunologically distinct serotypes (PV1, PV2, and PV3), meaning any effective vaccine had to be trivalent. In 1949 at Boston Children's Hospital, John Enders, Thomas Weller, and Frederick Robbins overturned the dogma that poliovirus was strictly neurotropic by culturing the Lansing strain in human embryonic skin, muscle, and kidney cells. Their method allowed high-titer propagation without myelin-contaminated brain tissue that caused allergic encephalomyelitis.

What followed was a profound scientific divergence over the anatomical compartmentalization of humoral immunity. At the University of Pittsburgh, Jonas Salk pursued a formalin-inactivated injectable vaccine (IPV), whereas Albert Sabin at the University of Cincinnati championed an orally administered live-attenuated vaccine (OPV). Their two platforms engaged completely different limbs of the human B-cell system:

• * Salk's Formalin Inactivation Kinetics and Systemic $\text{IgG}$: Salk propagated virulent type 1 (Mahoney), type 2 (MEF-1), and type 3 (Saukett) polioviruses in cynomolgus monkey kidney cultures, clarified the fluid through fine sintered-glass filters, and incubated it with 1:4,000 formalin at $37^\circ\text{C}$ and pH 7.0. Formaldehyde cross-linked the capsid proteins (VP1–VP4) along a first-order exponential inactivation curve until live infectious titer hit zero around day three to six. Salk then maintained incubation up to twelve days to drive residual infectivity below one particle per million doses. Tested in 1.8 million children in Thomas Francis Jr.'s 1954 trial and declared 80 to 90 percent effective against paralytic polio on April 12, 1955, intramuscular IPV elicited high titers of serum $\text{IgG}$. Those blood-borne antibodies intercepted poliovirus during its viremic transit to the spinal cord, preventing paralysis. Because intramuscular killed antigen does not prime gut-associated lymphoid tissue, however, IPV recipients generated minimal intestinal immunity and could still excrete wild virus in stool.
• * The April 1955 Cutter Filtration Failure: Within two weeks of Francis's announcement, paralytic polio struck children inoculated with IPV lots manufactured by Cutter Laboratories in Berkeley, California. Forensic investigation revealed a physical deviation from Salk's protocol: when viral harvests were filtered through asbestos-cellulose Seitz pads rather than fine sintered glass, cellular debris coagulated into microscopic protein aggregates that shielded trapped Mahoney type 1 virions from formaldehyde penetration. Roughly 120,000 children received live virus in two Cutter lots, paralyzing 200 recipients and contacts and killing eleven before mandatory membrane filtration eliminated aggregation survivors.
• * Sabin's Enteric Attenuation and Secretory $\text{IgA}$: By passaging the three serotypes at limiting dilution through monkey kidney cells at sub-physiological temperatures, Sabin isolated neuro-attenuated strains bearing key mutations in the $5'$ untranslated region internal ribosome entry site (IRES) that crippled translation in motor neurons while preserving replication in enterocytes. Tested across ten million Soviet children by Mikhail Chumakov in 1959 and licensed in 1961–1962, Sabin's oral vaccine replicated directly in the intestinal mucosa, stimulating Peyer's patch B cells to class-switch into dimeric secretory $\text{IgA}$ (sIgA) transported into the gut lumen. That mucosal sIgA neutralized wild poliovirus on contact in the alimentary tract, halting fecal-oral transmission across entire communities.

Because Sabin's RNA viruses carried only a few attenuating point mutations—including A481G in the type 2 IRES—intestinal replication occasionally selected back-mutations toward neurovirulence in roughly one per 2.4 million doses or spawned circulating vaccine-derived polioviruses. Modern eradication strategy unites both mechanisms. It deploys oral vaccines and genetically stabilized nOPV2 strains to extinguish mucosal transmission during outbreaks, then transitions to Salk's inactivated injection to maintain paralysis-free systemic $\text{IgG}$, reducing global polio incidence by over 99.9 percent since 1988 and certifying the eradication of wild types 2 and 3.